Treatment Overview > ASCO 2002 Lymphoma-Specific Abstracts

Last update: 02/06/2004

Search ASCO 

antibodies (Rituxan,
anti-CD22, HU1D10 etc.) 

Return to top

We apologize for the inconvenience, but links to ASCO abstracts have been changed on their website. To locate the article of interest within:

1) Copy the first few words of the abstract name. 
    (Drag thru it and press Ctrl+V)
 
2) Click Here to do an Advanced Search from the ASCO.org website 
 
3) Paste the name into the Search term Title box. 
     Click in the box and press (Ctrl+V).
 
4) Select  the year (2003, 2003), then click Search

• Rituximab and methylprednisolone for therapy of CLL Year: 2002 Abstract No: 1923

• Recombinant IgA antibodies against HLA class II: a novel immunotherapeutic approach against B cell lymphoma Year: 2002 Abstract No: 1877

• IELSG phase II study of rituximab in MALT lymphoma: final results Year: 2002 Abstract No: 1067 | PDF

• Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data Year: 2002 Abstract No: 1060

• Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell lymphomas. A single institution study. Year: 2002 Abstract No: 1139

• Neutrophil function is necessary for in vivo antitumor activity of rituximab in a severe combined immunodeficiency (SCID) mouse model Year: 2002 Abstract No: 1811

• Rituximab administration subsequent to ibritumomab tiuxetan (Zevalin) radioimmunotherapy Year: 2002 Abstract No: 30

• IL-2 plus rituximab results in clinical responses in advanced patients with non-Hodgkin's lymphoma related to the degree of NK expansion. Year: 2002 Abstract No: 1131

• Bendamustine/mitoxantrone/rituximab (BMR): a new effective treatment for refractory or relapsed indolent lymphomas Year: 2002 Abstract No: 1127

• Rituximab and methylprednisolone for therapy of CLL Year: 2002 Abstract No: 1923

• Anti-CD 20 monoclonal antibody (Rituximab) in cold agglutinin disease Year: 2002 Abstract No: 2645

Biologics: 
antisense, interferon, vaccines, etc. 

Return to top

• cDNA microarray evaluation of non-Hodgkin's lymphoma cells reveals multiple changes in gene expression profiles induced by Bcl-2 antisense (GenasenseTM). Year: 2002 Abstract No: 1905

• A meta-analysis of randomized studies evaluation the role of interferon alpha as treatment for follicular lymphoma (FL) Year: 2002 Abstract No: 1053

• Duration of therapy of colony stimulating factors in oncology Year: 2002 Abstract No: 99

• Custom-made idiotype immunotherapies produced by high throughput gene expression technology (Hi-GETTM) for follicular non-Hodgkin's lymphoma (f-NHL) patients Year: 2002 Abstract No: 77

• A phase 2 trial to evaluate the efficacy of recombinant idiotype vaccines in untreated follicular non-Hodgkin's lymphoma in the "watch-and-wait" period Year: 2002 Abstract No: 13

Radiolabeled 
antibodies

Return to top

• ⁹⁰Y ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity Year: 2002 Abstract No: 1061

• ⁹⁰Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma Year: 2002 Abstract No: 1064

• ⁹⁰Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-HodgkinÝs lymphoma (NHL) patients Year: 2002 Abstract No: 51

• Bexxar therapy (tositumomab and iodine I 131 tositumomab) has high response rates in the treatment of bulky low grade (LG) relapsed or refractory non-Hodgkin's lymphoma (NHL) Year: 2002 Abstract No: 17

• NOVEL: Radiolabeled BLyS protein (LR131) inhibits neoplastic B cell growth in vivo Year: 2002 Abstract No: 39

Extranodal

CNS, Ocular, 
Cutaneous, etc.

Return to top

• Chemotherapy +/- whole-brain irradiation (WBI) for primary CNS lymphoma (PCNSL) - first experience with a randomized trial Year: 2002 Abstract No: 298

• Any role for brain irradiation in the treatment of primary central nervous system lymphoma (PCNSL)? Year: 2002 Abstract No: 2075

• Combination antiviral therapy for EBV-associated primary central nervous system lymphoma Year: 2002 Abstract No: 26

• Treatment of ocular lymphoma Year: 2002 Abstract No: 297

• Waldeyer's ring lymphomas: the prognostic factors and the treatment outcome Year: 2002 Abstract No: 1138

T-cell NHL

Return to top

• The anti-CD25 recombinant immunotoxin LMB-2 shows antitumor activity in patients with cutaneous T-cell lymphoma. Year: 2002 Abstract No: 33

• High-dose chemotherapy and autologous blood stem cell support in patients with aggressive T-cell lymphomas Year: 2002 Abstract No: 1147

• Impact of induction and salvage therapy including high-dose chemotherapy with stem cell transplantation on peripheral T-cell and large B-cell lymphomas Year: 2002 Abstract No: 1145

• Analysis of molecular markers and targets in trials of depsipeptide, FR901228, a histone deacetylase inhibitor with clinical activity in T-cell lymphoma Year: 2002 Abstract No: 88

Bone Marrow Transplants

Return to top

• Early relapse before day-100 following high-dose therapy with autologous stem-cells transplantation (ASCT) for non Hodgkin lymphoma (NHL) and Hodgkin disease (HD) patients Year: 2002 Abstract No: 1689

• Autologous vs allogeneic transplantation for follicular lymphoma: report from the IBMTR and ABMTR Year: 2002 Abstract No: 1656

• ALLOBMT AFTER AUTO: Allogeneic transplantation in patients that relapsed after autologous transplantation for lymphoma: a report from the International Bone Marrow Transplant Registry Year: 2002 Abstract No: 1655

Factors in Prognosis/Outcomes

Return to top

• Histological and Clinical Prognostic Factors in Follicular Lymphoma: Proposal for a Prognostic Model [131]. 

• Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor study Year: 2002 Abstract No: 1573

• Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma Year: 2002 Abstract No: 1137

• Applicability of International Prognostic Index in non-Hodgkin's lymphoma in Pakistan Year: 2002 Abstract No: 2642

• Transformation of follicular lymphoma: prognostic factors and effect on survival Year: 2002 Abstract No: 1129

Chemotherapy

Return to top

• Phase II study of dexamethasone, ifosfamide, cisplatin and etoposide delivered on an outpatient basis (O-DICE), as salvage chemotherapy for patients with relapsed and refractory lymphoma Year: 2002 Abstract No: 1136

• CONTINUOUS INFUSION: Phase I trial of gemcitabine given as a 96 hour continuous intravenous infusion. Year: 2002  Abstract No: 2137

• GASTRIC HIGH GRADE NHL: Management of high-grade gastric lymphoma with chemotherapy alone Year: 2002 Abstract No: 1155

• DHAOx SALVAGE TREATMENT: Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma Year: 2002 Abstract No: 2653

• LIPOSOMAL VINCRISTINE: A phase II study of liposomal vincristine in CHOP with rituximab for elderly patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL). Year: 2002 Abstract No: 1132

• LIPOSOMAL DOXORUBICIN: A phase I/II trial of liposomal doxorubicin (TLC D-99, Myocet) with cyclophosphamide, vincristine, and prednisone in newly diagnosed aggressive non-Hodgkins lymphoma (NHL) Year: 2002 Abstract No: 1133

• LIPOSOMAL DOXORUBICIN AIDS-RELATED  NHL: Treatment of newly diagnosed AIDS-related lymphomas with liposomal doxorubicin (TLC-D99, Myocet) combined with cyclophosphamide, vincristine, and prednisone: results of a phase I/II trial Year: 2002   Abstract No: 1135

MISC

Return to top

• BURKITT'S TREATMENT: The Magrath regimen is effective in older adults with Burkitt's and Burkitt-like lymphomas Year: 2002 Abstract No: 1150

• CELLULAR TARGET: Platelet-derived growth factor receptor (PDGF-R) α and β expression in human malignancy Year: 2002 Abstract No: 1774

• WALDENSTROM'S: Expression of serotherapy target antigens in lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia). Year: 2002 Abstract No: 1112

• SECONDARY INFECTION & NHL: Collection of infectious disease and economic outcomes for non-Hodgkin¢s lymphoma and multiple myeloma patients admitted for infectious complications utilizing a Palm^TM handheld. Year: 2002 Abstract No: 2607

• ANEMIA: Epoetin beta is effective in patients with relapsed lymphoma treated with the Cologne high-dose sequential chemotherapy regimen  Year: 2002 Abstract No: 2637